Weibo Yin - Concord Medical Independent Director and Member of Audit Committee
| CCM Stock | USD 5.00 0.56 12.61% |
Director
Dr. Weibo Yin serves as Independent Director of Concord Medical Services Holdings Ltd., since November 29, 2011. He is the Honorary President of Chinese Society of Radiation Oncology and a board member of the International Congress of Radiation Oncology. Dr. Yin has served various positions such as professor emeritus, professor, associate professor and resident doctor in Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical University since 1957. In addition, Dr. Yin has published 155 research papers on radiation oncology, in 32 of which he was the first author. Dr. Yin received his M.D. degree from Peking Union Medical University in 1957. since 2011.
| Age | 89 |
| Tenure | 13 years |
| Address | East Zone, Hanwei Plaza, Beijing, China, 100020 |
| Phone | 86 10 5903 6688 |
| Web | https://www.concordmedical.com |
Concord Medical Management Efficiency
The company has Return on Asset of (0.044) % which means that on every $100 spent on assets, it lost $0.044. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.324) %, meaning that it generated no profit with money invested by stockholders. Concord Medical's management efficiency ratios could be used to measure how well Concord Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Equity is likely to grow to 0.27, while Return On Tangible Assets are likely to drop (0.06). At this time, Concord Medical's Other Current Assets are very stable compared to the past year. As of the 25th of November 2024, Intangible Assets is likely to grow to about 435.8 M, while Other Assets are likely to drop about 26.2 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Emil Hassan | National HealthCare | 72 | |
| William Frist | Select Medical Holdings | 69 | |
| Richard LaRoche | National HealthCare | 74 | |
| David Larson | American Shared Hospital | 78 | |
| Daniel Thomas | Select Medical Holdings | 62 | |
| Leslye Katz | Encompass Health Corp | 66 | |
| Russell Carson | Select Medical Holdings | 77 | |
| James Ely | Select Medical Holdings | 63 | |
| Yvonne Curl | Encompass Health Corp | 65 | |
| Daniel Kelly | American Shared Hospital | 67 | |
| Ernest Burgess | National HealthCare | 79 | |
| Marilyn Tavenner | Select Medical Holdings | 69 | |
| Sandra Lawrence | American Shared Hospital | 61 | |
| Joan Herman | Encompass Health Corp | 67 | |
| Charles Elson | Encompass Health Corp | 60 | |
| Donald Correll | Encompass Health Corp | 70 | |
| Parvinderjit Khanuja | Select Medical Holdings | 62 | |
| Christopher Reidy | Encompass Health Corp | 64 | |
| Katherine Davisson | Select Medical Holdings | 53 | |
| Bryan Cressey | Select Medical Holdings | 71 | |
| Saim Ozyurek | American Shared Hospital | 45 | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.044 |
Concord Medical Services Leadership Team
Elected by the shareholders, the Concord Medical's board of directors comprises two types of representatives: Concord Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Concord. The board's role is to monitor Concord Medical's management team and ensure that shareholders' interests are well served. Concord Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Concord Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xun Liu, Financial Controller | ||
| Zheng Cheng, President, Director and Member of Investment Committee | ||
| Qing Pan, Director | ||
| Matthew Callister, Chief Medical Officer | ||
| Fu Xiao, Chief Operating Officer | ||
| Jianyu Yang, Chairman, CEO, Chairman of Compensation Committee and Member of Investment Committee | ||
| Boxun Zhang, Independent Director | ||
| Yaw Yap, CFO and Member of Investment Committee | ||
| Ting Lee, Independent Non-Executive Director | ||
| Weibo Yin, Independent Director and Member of Audit Committee | ||
| Liping Zhang, Independent Director | ||
| Yue Yu, Director |
Concord Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Concord Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.044 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.90) % | ||||
| Current Valuation | 466.69 M | ||||
| Shares Outstanding | 2.82 M | ||||
| Shares Owned By Insiders | 17.99 % | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 11.4 K | ||||
| Price To Earning | (3.90) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Concord Medical Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Concord Medical. If investors know Concord will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Concord Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.98) | Revenue Per Share 107.978 | Quarterly Revenue Growth (0.23) | Return On Assets (0.04) | Return On Equity (0.32) |
The market value of Concord Medical Services is measured differently than its book value, which is the value of Concord that is recorded on the company's balance sheet. Investors also form their own opinion of Concord Medical's value that differs from its market value or its book value, called intrinsic value, which is Concord Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Concord Medical's market value can be influenced by many factors that don't directly affect Concord Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Concord Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Concord Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Concord Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.